Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of some unusual options trading on Wednesday. Investors bought 1,002 put options on the company. This is an increase of approximately 1,791% compared to the average daily volume of 53 put options.
MRVI has been the subject of a number of research reports. Robert W. Baird reduced their price objective on Maravai LifeSciences from $48.00 to $40.00 in a research note on Friday, May 6th. Morgan Stanley dropped their target price on Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, February 25th.
NASDAQ:MRVI traded down $1.08 during trading hours on Thursday, reaching $25.73. The stock had a trading volume of 14,573 shares, compared to its average volume of 1,934,326. The company has a debt-to-equity ratio of 0.80, a quick ratio of 6.55 and a current ratio of 7.14. The stock has a 50 day simple moving average of $32.42 and a 200 day simple moving average of $34.62. Maravai LifeSciences has a 12-month low of $23.16 and a 12-month high of $63.55. The stock has a market cap of $6.57 billion, a P/E ratio of 16.86 and a beta of 0.76.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.43 by $0.11. Maravai LifeSciences had a return on equity of 96.51% and a net margin of 25.25%. The business had revenue of $244.30 million during the quarter, compared to analysts’ expectations of $232.29 million. During the same period in the previous year, the business earned $0.26 earnings per share. The firm’s revenue was up 64.8% on a year-over-year basis. On average, equities analysts expect that Maravai LifeSciences will post 1.85 earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. Select Equity Group L.P. raised its holdings in Maravai LifeSciences by 69.5% in the 4th quarter. Select Equity Group L.P. now owns 20,542,503 shares of the company’s stock worth $860,731,000 after purchasing an additional 8,420,492 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Maravai LifeSciences by 44.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 8,003,021 shares of the company’s stock valued at $335,326,000 after buying an additional 2,459,692 shares during the last quarter. BlackRock Inc. lifted its position in Maravai LifeSciences by 30.7% during the fourth quarter. BlackRock Inc. now owns 6,053,047 shares of the company’s stock valued at $253,622,000 after purchasing an additional 1,420,288 shares during the period. Ardevora Asset Management LLP acquired a new position in Maravai LifeSciences during the fourth quarter valued at $59,130,000. Finally, Norges Bank acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth about $39,039,000. 50.18% of the stock is currently owned by institutional investors and hedge funds.
About Maravai LifeSciences (Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
Receive News & Ratings for Maravai LifeSciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Maravai LifeSciences and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
